Log in

NASDAQ:MASIMasimo Stock Price, Forecast & News

$217.19
-1.06 (-0.49 %)
(As of 08/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$214.23
Now: $217.19
$219.06
50-Day Range
$217.50
MA: $228.41
$246.81
52-Week Range
$139.36
Now: $217.19
$258.00
Volume530,862 shs
Average Volume489,268 shs
Market Capitalization$11.93 billion
P/E Ratio56.27
Dividend YieldN/A
Beta0.87
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. In addition, the company offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, and handheld capnograph and capnometer devices; and O3 regional oximetry for tissue oxygen saturation measurement. Further, it provides Patient SafetyNet, a surveillance, remote monitoring, and clinician notification solution; MyView, a wireless presence-detection system; and connectivity devices. Additionally, the company offers Trace, a patient data visualization and reporting software that monitors Masimo Root and Radical-7. The company provides its products directly, as well as through distributors and original equipment manufacturers partners to hospitals, emergency medical service providers, physician offices, long term care facilities, veterinarians and consumers. Masimo Corporation was founded in 1989 and is headquartered in Irvine, California.
Read More
Masimo logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:MASI
CUSIP57479510
Phone949-297-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$937.84 million
Cash Flow$3.87 per share
Book Value$24.47 per share

Profitability

Net Income$196.22 million

Miscellaneous

Employees1,600
Market Cap$11.93 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$217.19
-1.06 (-0.49 %)
(As of 08/4/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MASI News and Ratings via Email

Sign-up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Masimo (NASDAQ:MASI) Frequently Asked Questions

How has Masimo's stock been impacted by COVID-19 (Coronavirus)?

Masimo's stock was trading at $182.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MASI shares have increased by 18.9% and is now trading at $217.19.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Masimo?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Masimo
.

When is Masimo's next earnings date?

Masimo is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Masimo
.

How were Masimo's earnings last quarter?

Masimo Co. (NASDAQ:MASI) released its quarterly earnings data on Tuesday, July, 28th. The medical equipment provider reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.07. The medical equipment provider earned $301 million during the quarter, compared to analysts' expectations of $290.09 million. Masimo had a net margin of 21.22% and a return on equity of 16.49%. The firm's revenue was up 30.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.76 earnings per share.
View Masimo's earnings history
.

What price target have analysts set for MASI?

7 Wall Street analysts have issued twelve-month target prices for Masimo's stock. Their forecasts range from $175.00 to $255.00. On average, they expect Masimo's share price to reach $221.17 in the next year. This suggests a possible upside of 1.8% from the stock's current price.
View analysts' price targets for Masimo
.

Has Masimo been receiving favorable news coverage?

News stories about MASI stock have trended somewhat negative on Wednesday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Masimo earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the medical equipment provider a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the stock's share price in the next few days.
View the latest news about Masimo
.

Are investors shorting Masimo?

Masimo saw a decrease in short interest in July. As of July 15th, there was short interest totaling 925,800 shares, a decrease of 31.4% from the June 30th total of 1,350,000 shares. Based on an average daily trading volume, of 647,200 shares, the days-to-cover ratio is presently 1.4 days. Currently, 1.9% of the company's shares are sold short.
View Masimo's Current Options Chain
.

Who are some of Masimo's key competitors?

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Walt Disney (DIS), Shopify (SHOP), Paypal (PYPL), Okta (OKTA), Mastercard (MA), Trade Desk (TTD) and Twilio (TWLO).

Who are Masimo's key executives?

Masimo's management team includes the following people:
  • Mr. Joseph E. Kiani, Founder, CEO & Chairman (Age 54)
  • Mr. Micah Young, Exec. VP of Fin. & CFO (Age 40)
  • Mr. Anand Sampath, Chief Operating Officer (Age 53)
  • Dr. Steven J. Barker, Chairman of Scientific Advisory Board, Chief Science Officer & Director (Age 74)
  • Mr. Thomas Samuel McClenahan, Exec. VP, Gen. Counsel & Corp. Sec. (Age 46)

What is Masimo's stock symbol?

Masimo trades on the NASDAQ under the ticker symbol "MASI."

Who are Masimo's major shareholders?

Masimo's stock is owned by a number of institutional and retail investors. Top institutional investors include Raymond James & Associates (0.57%), Sumitomo Mitsui Trust Holdings Inc. (0.38%), Obermeyer Wood Investment Counsel Lllp (0.36%), UBS Group AG (0.36%), Strs Ohio (0.31%) and First Trust Advisors LP (0.26%). Company insiders that own Masimo stock include Adam Mikkelson, Anand Sampath, Bilal Muhsin, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan and Yongsam Lee.
View institutional ownership trends for Masimo
.

Which major investors are selling Masimo stock?

MASI stock was sold by a variety of institutional investors in the last quarter, including BNP PARIBAS ASSET MANAGEMENT Holding S.A., Scout Investments Inc., UBS Group AG, Candriam Luxembourg S.C.A., Mckinley Capital Management LLC Delaware, Handelsinvest Investeringsforvaltning, Eukles Asset Management, and B & T Capital Management DBA Alpha Capital Management. Company insiders that have sold Masimo company stock in the last year include Adam Mikkelson, Anand Sampath, Bilal Muhsin, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Thomas Samuel Mcclenahan, and Yongsam Lee.
View insider buying and selling activity for Masimo
.

Which major investors are buying Masimo stock?

MASI stock was bought by a variety of institutional investors in the last quarter, including Sumitomo Mitsui Trust Holdings Inc., First Trust Advisors LP, Assenagon Asset Management S.A., State of Alaska Department of Revenue, Nisa Investment Advisors LLC, Gulf International Bank UK Ltd, Oregon Public Employees Retirement Fund, and Tributary Capital Management LLC.
View insider buying and selling activity for Masimo
.

How do I buy shares of Masimo?

Shares of MASI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Masimo's stock price today?

One share of MASI stock can currently be purchased for approximately $217.19.

How big of a company is Masimo?

Masimo has a market capitalization of $11.93 billion and generates $937.84 million in revenue each year. The medical equipment provider earns $196.22 million in net income (profit) each year or $3.22 on an earnings per share basis. Masimo employs 1,600 workers across the globe.

What is Masimo's official website?

The official website for Masimo is www.masimo.com.

How can I contact Masimo?

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The medical equipment provider can be reached via phone at 949-297-7000 or via email at [email protected]

This page was last updated on 8/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.